Key HighlightsThe FDA has cleared Fayuvi from Ultragenyx, representing the first therapy to address the underlying cause of Sanfilippo syndrome Type AShares of Ultragenyx (RARE) surged 13% to reach $14.50 in Thursday’s trading session after the regulatory milestoneThe treatment is delivered as a single-dose gene therapy via intravenous infusion, utilizing a modified viral vector to penetrate the brain barrierTrial participants receiving Fayuvi demonstrated a 23.5-point advantage in cognitive assessments compared to those without treatmentThe approval represents Ultragenyx’s second gene therapy to gain regulatory clearance and marks the company’s sixth overall FDA nodUltragenyx (RARE) shares rallied 13% to finish at $14.50 on Thursday following the FDA’s decision to approve Fayuvi, a groundbreaking gene therapy designed to treat Sanfilippo syndrome Type A, a devastating hereditary disorder that causes progressive neurological decline in pediatric patients.Ultragenyx Pharmaceutical Inc., RAREUntil now, families affected by this condition had no options to tackle the disease at its source. Medical professionals were limited to treating symptoms as they emerged.The mechanism behind Fayuvi involves addressing a critical deficiency in the sulfamidase enzyme. When this enzyme is absent or insufficient, heparan sulfate—a complex sugar compound—accumulates within brain tissue, triggering ongoing cellular destruction and neurological deterioration.Administration involves a single intravenous infusion delivered directly into the patient’s circulatory system. The treatment leverages AAV9, a genetically modified virus engineered to safely transport therapeutic material across the blood-brain barrier and into the central nervous system.The regulatory decision drew upon clinical evidence spanning up to eight years of patient monitoring. Data revealed that children treated with Fayuvi achieved cognitive assessment scores 23.5 points superior to those of their untreated counterparts.Scientists additionally measured heparan sulfate concentrations directly within cerebrospinal fluid samples. Results demonstrated that the therapy maintained ongoing reduction of the harmful substance in patients who received treatment.Regulatory Clearance and Patient AccessDistribution of Fayuvi will be restricted to Qualified Treatment Centers—specialized medical facilities equipped and certified to deliver gene therapy treatments. Ultragenyx anticipates launching an online resource within days to help families identify approved administration sites.The biotech firm projects initial product shipments to these certified centers will occur within a 30 to 60-day window. According to company estimates, approximately 3,000 to 5,000 children in reachable markets currently live with Sanfilippo syndrome Type A.Without intervention, patients typically survive to approximately 15 years of age. This sobering statistic highlights the critical importance of Thursday’s regulatory breakthrough for families navigating this diagnosis.Production Infrastructure and Company MilestonesProduction of Fayuvi takes place across two dedicated manufacturing sites located in Massachusetts and Ohio. This dual-facility strategy aims to ensure reliable therapeutic supply as demand materializes.Thursday’s approval represents the second gene therapy in Ultragenyx’s portfolio to gain market authorization and brings the company’s total FDA approvals to six. The organization has systematically expanded its rare disease treatment pipeline in recent years.Regulatory clearance followed the FDA’s comprehensive evaluation of clinical evidence, with researchers monitoring both cognitive outcomes and biochemical indicators throughout the study period.While Ultragenyx has not yet disclosed pricing for Fayuvi, one-time gene therapies typically command substantial list prices reflecting their complex manufacturing requirements and single-administration format.Qualified Treatment Centers gained the ability to place orders for the therapy immediately following Thursday’s approval announcement.The post Ultragenyx (RARE) Shares Surge 13% on Groundbreaking Gene Therapy FDA Green Light appeared first on Blockonomi.